Given the consequences of PTEN loss or alterations in the PI3K-AKT signaling axis on immunosuppression in other cancers, targeting PI3K signaling in conjunction with immune checkpoint inhibition as well as VEGF inhibition may offer opportunities for the combination of targeted and immunotherapies in localized CRPC. Here, VEGFA is linked to cancer.